Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis

References

• Parisi R, Symmons D, Griffiths CE, et al.; On behalf of IMPACT team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013;133(2):377–385.
   PubMed Web of Science ®Google Scholar
• Yasaman M, Goldenberg G. New systemic therapies for psoriasis. Cutis. 2015;95:155–160.
   PubMed Web of Science ®Google Scholar
• Kopp T, Riedl E, Bangert C, et al. Targeting of interleukin-23. Nature. 2015;521(7551):222–226.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271.
   PubMed Web of Science ®Google Scholar
• Warren RB. Efficacy and safety of emerging immunotherapies in psoriasis. Immunotherapy. 2015;7:119–133.
   PubMed Web of Science ®Google Scholar
• di Cesare A, di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339–1350.
   PubMed Web of Science ®Google Scholar
• Coimbra S, Oliveira H, Reis F, et al. Interleukin (IL)-22, IL-17, IL-23, IL8, vascular endothelial growth factor and tumour necrosis factor alpha levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol. 2010;163(6):1282–1290.
   PubMed Web of Science ®Google Scholar
• Chang SH, Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res. 2007;17:435–440.
   PubMed Web of Science ®Google Scholar
• Wright JF, Guo Y, Quazi A, et al. Identification of an interleukin 17F/17A heterodimer in activated human CD4+Tcells. J Biol Chem. 2007;282:13447–13455.
   PubMed Web of Science ®Google Scholar
• Kuestner RE, Taft DW, Haran A, et al. Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol. 2007;179:5462–5473.
   PubMed Web of Science ®Google Scholar
• Wright JF, Bennett F, Li B, et al. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL17RC receptor complex. J Immunol. 2008;181:2799–2805.
   PubMed Web of Science ®Google Scholar
• Ramirez-Carrozzi V, Sambandam A, Luis E, et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol. 2011;12:1159–1166.
   PubMed Web of Science ®Google Scholar
• Chang SH, Reynolds JM, Pappu BP, et al. Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity. 2011;35:611–621.
   PubMed Web of Science ®Google Scholar
• Rickel EA, Siegel LA, Yoon BR, et al. Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J Immunol. 2008;181:4299–4310.
   PubMed Web of Science ®Google Scholar
• Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9:556–567.
   PubMed Web of Science ®Google Scholar
• Shi Y, Ullrich SJ, Zhang J, et al. A novel cytokine receptor-ligand pair. Identification, molecular characterization, and in vivo immunomodulatory activity. J Biol Chem. 2000;275:19167–19176.
   PubMed Web of Science ®Google Scholar
• Isailovic N, Daigo K, Mantovani A, et al. Interleukin-17 and innate immunity in infections and chronic inflammation. J Autoimmun. 2015;60:1–11.
   PubMed Web of Science ®Google Scholar
• Cella M, Fuchs A, Vermi W, et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature. 2009;457(7230):722–725.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Gordon KB, Fakharzadeh S, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012;166(4):861–872.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Gordon KB. New and emerging therapies in psoriasis. Semin Cutan Med Surg. 2014;33:37–41.
   PubMed Web of Science ®Google Scholar
• Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72–72.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012;359(1–2):419–429.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Duffin KC, Bissonnette R, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373(2):136–144.
   PubMed Web of Science ®Google Scholar
• Papp K, Thaçi D, Reich K, et al. Tildrakizumab (MK-3222), an anti- IL23p19 monoclonal antibody, improves psoriasis in a phase 2b randomized placebo- controlled trial. Br J Dermatol. 2015;173(4):930–939.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A 48 weeks study of three different dose regimens of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis (Randomised, dose-ranging, active-comparator-controlled (Ustekinumab), double-blind within dose groups of BI 655066). 2017 Jan 8th. Available from: https://clinicaltrials.gov/ct2/show/NCT02054481?term=BI655066+psoriasis&rank=7
   Google Scholar
• Galluzzo M, D’Adamio S, Bianchi L, et al. Brodalumab for the treatment of psoriasis. Expert Rev Clinic Immunol. 2016;12(12):1255–1271.
   PubMed Web of Science ®Google Scholar
• Papp KA, Reid C, Foley P, et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol. 2012;132(10):2466–2469.
   PubMed Web of Science ®Google Scholar
• Papp KA, Reich K, Paul C, et al. A prospective Phase 3, randomized, double-blind, placebo controlled study of brodalumab in patients with moderate-to severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–286.
   PubMed Web of Science ®Google Scholar
• Martin DA, Churchill M, Flores-Suarez L, et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther. 2013;15(5):R164.
   PubMed Web of Science ®Google Scholar
• Osamu N, Hirotaka N, Koji S, et al. Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo controlled study. J Dermatol Sci. 2014;75(3):201–204.
   PubMed Web of Science ®Google Scholar
• Endres CJ, Salinger DH, Kӧck K, et al. Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies. J Clin Pharmacol. 2014;54(11):1230–1238.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drugs administration. FDA briefing document dermatologic and ophthalmic drugs advisory committee meeting July 19, 2016. 2017 Jan 8Th. Available from: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/ucm511356.htm.
   Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti interleukin-17–receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181–1189.
   PubMed Web of Science ®Google Scholar
• Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014;71(6):1183–1190.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Niirob H, Ootaki K, et al. Brodalumab, a human antiinterleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy andsafety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81(1):44–52.
   PubMed Web of Science ®Google Scholar
• Umezawa Y, Nakagawa H, Niiro H, et al. Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2016 Nov;30(11):1957–1960.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328.
   PubMed Web of Science ®Google Scholar
• Papp K, Reich K, Leonardi C, et al. Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis: results of AMAGINE-1, a phase 3, randomized, double-blind, placebo controlled study through week 12.; Presented at the 73rd annual meeting of the American academy of dermatology; San Francisco, CA. 2015 March 20–24.
   Google Scholar
• AbuHilal M, Walsh S, Shear N. The role of IL-17 in the pathogenesis of psoriasis and update on IL-17 inhibitors for the treatment of plaque psoriasis. J Cutan Med Surg. 2016;20:509–516.
   PubMed Web of Science ®Google Scholar
• Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332(6025):65–68.
   PubMed Web of Science ®Google Scholar
• Boisson B, Wang C, Pedergnana V, et al. An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity. 2013;39(4):676–686.
   PubMed Web of Science ®Google Scholar
• Farahnik B, Beroukhim K, Nakamura M, et al. Anti-IL-17 agents for psoriasis: a review of phase III data. J Drugs Dermatol. 2016;15(3):311–316.
   PubMedGoogle Scholar
• Hueber W, Sands B, Lewitzky S, et al. Secukinumab, a human anti-IL17a monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomized, double-blind placebo controlled trial. Gut. 2012;61(12):1693–1700.
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Vermiere S, et al. A randomized, double blind, placebo controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn’s disease. Gastroenterology. 2012;143(3):E26.
   PubMed Web of Science ®Google Scholar
• Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998;139(5):846–850.
   PubMed Web of Science ®Google Scholar
• Kurd SK, Troxel AB, Crits-Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891–895.
   PubMed Web of Science ®Google Scholar
• Danesh MJ, Kimball AB. Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. J Am Acad Dermatol. 2016;74:190–192.
   PubMed Web of Science ®Google Scholar
• Celgene Corporation. Highlights of prescribing information. 2017 Jan 8th. Available from: http://www.otezla.com/otezla-prescribinginformation.pdf
   Google Scholar
• AstraZeneca. 2017 Jan 8th. “AstraZeneca enters licensing agreements with LEO Pharma in skin diseases”. http://www.astrazeneca.com.
   Google Scholar
• Valeant Pharmaceuticals International. 2017 Jan 8th. Valeant Pharmaceuticals announces new licensing arrangement for brodalumab in Europe. Available from:http://www.valeant.com
   Google Scholar
• Drug.com. FDA advisory committee recommends approval of brodalumab for treatment of moderate-to-severe plaque psoriasis. 2017 Jan 8th. Available from: https://www.drugs.com/nda/brodalumab_160719.html
   Google Scholar
• Medscape Dermatology. FDA panel backs approval of psoriasis drug brodalumab. 2017 Jan 8th. Avilable from: http://www.medscape.com/viewarticle/866406?nlid=108537_1585&src=WNL_mdplsfeat_160726_mscpedit_derm&uac=208695CJ&spon=33&impID=1166274&faf=1
   Google Scholar
• Strober B, Papp KA, Lebwohl M, et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016 Jul;75(1):77–82.
   PubMed Web of Science ®Google Scholar
• Katugampola RP, Lewis VJ, Finlay AY. The dermatology life quality index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol. 2007;156:945–950.
   PubMed Web of Science ®Google Scholar
• Revicki DA, Willian MK, Menter A, et al. Relationship between clinical response to therapy and health related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatol Basel Switz. 2008;216:260–270.
   PubMed Web of Science ®Google Scholar
• Levin AA, Gottlieb AB, Au SC. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies. J Drugs Dermatol. 2014 Jul;13(7):848–853.
   PubMed Web of Science ®Google Scholar
• Yeung H, Wan J, van Voorhees AS, et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol. 2013 Jan;68(1):64–72.
   PubMed Web of Science ®Google Scholar
• Gniadecki R, Kragballe K, Dam TN, et al. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011 May;164(5):1091–1096.
   PubMed Web of Science ®Google Scholar
• Takeshita J, Callis Duffin K, Shin DB, et al. Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. J Am Acad Dermatol. 2014 Oct;71(4):633–641.
   PubMed Web of Science ®Google Scholar
• Langenbruch A, Radtke MA, Krensel M, et al. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014;171(5):1123–1128.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44(2):183–193.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Poon K-YT-Y, Channual JC, et al. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244–1250.
   PubMed Web of Science ®Google Scholar
• de Boer OJ, van der Meer JJ, Teeling P, et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol. 2010;220(4):499–508.
   PubMed Web of Science ®Google Scholar
• Csiszar A, Ungvari Z. Synergistic effects of vascular IL-17 and TNFalpha may promote coronary artery disease. Med Hypotheses. 2004;63(4):696–698.
   PubMed Web of Science ®Google Scholar